Cargando…

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies

T-cell malignancies can be divided into precursor (T-acute lymphoblastic leukemia/lymphoblastic lymphoma, T-ALL/LBL) and mature T-cell neoplasms, which are comprised of 28 different entities. Most of these malignancies are aggressive with rather poor prognosis. Prognosis of relapsed/refractory (R/R)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polgárová, Kamila, Otáhal, Pavel, Šálek, Cyril, Pytlík, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121778/ https://www.ncbi.nlm.nih.gov/pubmed/35600381 http://dx.doi.org/10.3389/fonc.2022.876758

Ejemplares similares

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
por: Pytlik, Robert, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome
por: Štach, Martin, et al.
Publicado: (2023)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience
por: Polgárová, Kamila, et al.
Publicado: (2022)

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis
por: Grigor, Emma J M, et al.
Publicado: (2017)

Cardiovascular disease and chimeric antigen receptor cellular therapy
por: Rao, Anjali, et al.
Publicado: (2022)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Human Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy
por: Landi, Daniel, et al.
Publicado: (2014)

Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy
por: Lipe, Demis N., et al.
Publicado: (2023)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis
por: Jang, Jong Keon, et al.
Publicado: (2022)

Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis
por: Chen, Li-Rong, et al.
Publicado: (2022)

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)

The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy
por: Wang, Yang, et al.
Publicado: (2022)

Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series
por: Dhaliwal, Armaan, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
por: Totzeck, Matthias, et al.
Publicado: (2022)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
por: Marzal-Alfaro, María Belen, et al.
Publicado: (2021)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
por: Shen, Chunyi, et al.
Publicado: (2020)

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity
por: Keane, John T., et al.
Publicado: (2021)

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021)

Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
por: Miyao, Kotaro, et al.
Publicado: (2023)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells
por: Phanthaphol, Nattaporn, et al.
Publicado: (2021)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
por: Duran-Struuck, Raimon, et al.
Publicado: (2019)

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
por: Stein, Andrew M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ibsrn0ahirm5gfqb5qosburbts